{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:42:33Z","timestamp":1788864153819,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008459","name":"University of Calgary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106394","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T04:11:54Z","timestamp":1742184714000},"page":"106394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Magnetic resonance imaging characteristics of myelin oligodendrocyte glycoprotein antibody positive patients -validation of current diagnostic criteria"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-9535","authenticated-orcid":false,"given":"Jodie M.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napo","family":"Kasirye-Mbugua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarina","family":"Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.msard.2025.106394_bib0001","first-page":"00431","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"S1474-4422","author":"Banwell","year":"2023","journal-title":"Lancet. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106394_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209303","article-title":"Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease","volume":"102","author":"Cacciaguerra","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2025.106394_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.msard.2025.106394_bib0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/WCO.0000000000000681","article-title":"Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults","volume":"32","author":"Cobo-Calvo","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106394_bib0005","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2023-333227","article-title":"Validation of the international MOGAD panel proposed criteria: a single-centre US study","volume":"95","author":"Filippatou","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106394_bib0006","unstructured":"Flanagan, E.P., Tillema J.-M. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis (last update November 15, 2024). In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on Jan 29, 2025)."},{"issue":"10","key":"10.1016\/j.msard.2025.106394_bib0007","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41582-024-01005-2","article-title":"The influence of MOGAD on diagnosis of multiple sclerosis using MRI","volume":"20","author":"Geraldes","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2025.106394_bib0008","doi-asserted-by":"crossref","first-page":"15986","DOI":"10.3390\/ijms242115986","article-title":"Beyond myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: alternative causes of optic neuritis","volume":"24","author":"Greco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106394_bib0009","first-page":"1","article-title":"A quality assessment of aquaporin-4 myelin oligodendrocyte glycoprotein antibody testing","author":"Krett","year":"2022","journal-title":"Can J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2025.106394_bib0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106394_bib0011","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106394_bib0012","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti - myelin oligodendrocyte glycoprotein antibody - associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106394_bib0013","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features","volume":"13","author":"Sechi","year":"2022","journal-title":"Diagnosis, Manage. Front Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106394_bib0014","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different Central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106394_bib0015","doi-asserted-by":"crossref","first-page":"1192644","DOI":"10.3389\/fneur.2023.1192644","article-title":"High level of agreement in a fixed versus live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting","volume":"14","author":"Smith","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.msard.2025.106394_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209321","article-title":"Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children","volume":"103","author":"Varley","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106394_bib0017","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters Waters","year":"2019","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:41:16Z","timestamp":1762602076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":17,"alternative-id":["S2211034825001361"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106394","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic resonance imaging characteristics of myelin oligodendrocyte glycoprotein antibody positive patients -validation of current diagnostic criteria","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106394"}}